The federal political pressure on drug pricing may have stalled on Washington gridlock, but as we previously covered here at CBPartners, it is driving real change at the state level. State lawmakers are better positioned to develop laws that regulate pharmaceutical stakeholders, given the more manageable scope of state markets,…
Indirect Pricing Controls Through PBM Regulation: If You Can’t Beat Them, Arrange to Have Them Beaten
